ALT - Altimmune Inc Stock Price, Fair Value and News

7.19USD-0.01 (-0.14%)Delayed as of 26 Apr 2024, 01:36 pm ET

Market Summary

USD7.19-0.01

Delayedas of 26 Apr 2024, 01:36 pm

-0.14%

ALT Stock Price

View Fullscreen

ALT RSI Chart

ALT Valuation

Market Cap

511.9M

Price/Earnings (Trailing)

-5.79

Price/Sales (Trailing)

1.2K

EV/EBITDA

-3.88

Price/Free Cashflow

-6.75

ALT Price/Sales (Trailing)

ALT Profitability

EBT Margin

-22930.75%

Return on Equity

-45.57%

Return on Assets

-41.99%

Free Cashflow Yield

-14.82%

ALT Fundamentals

ALT Revenue

Revenue (TTM)

426.0K

Rev. Growth (Yr)

221.74%

Rev. Growth (Qtr)

-89.78%

ALT Earnings

Earnings (TTM)

-88.4M

Earnings Growth (Yr)

-46.08%

Earnings Growth (Qtr)

-53.07%

Breaking Down ALT Revenue

52 Week Range

2.347.42

(Low)(High)

Last 7 days

4.8%

Last 30 days

-16.5%

Last 90 days

-22.6%

Trailing 12 Months

38.3%

How does ALT drawdown profile look like?

ALT Financial Health

Current Ratio

17.26

Debt/Equity

Debt/Cashflow

-128.45

ALT Investor Care

Shares Dilution (1Y)

43.84%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	426.0K
2022	0	0	0	0
2021	6.8M	6.2M	3.4M	4.4M
2020	5.1M	4.2M	6.4M	8.2M
2019	10.6M	9.8M	7.8M	5.8M
2018	13.1M	12.5M	10.6M	10.3M
2017	3.1M	5.4M	9.0M	10.7M
2016	4.6M	4.2M	3.9M	3.8M
2015	13.5M	11.0M	11.2M	10.6M
2014	15.2M	14.5M	12.0M	10.2M
2013	25.5M	23.5M	20.3M	17.9M
2012	24.1M	24.0M	25.4M	25.2M
2011	21.8M	22.6M	23.4M	24.3M
2010	0	0	0	21.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Altimmune Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 02, 2024	roberts m scot	acquired	-	-	7,775	chief scientific officer
Feb 02, 2024	garg vipin k	acquired	-	-	18,950	president and ceo
Feb 02, 2024	garg vipin k	sold (taxes)	-78,064	9.32	-8,376	president and ceo
Feb 02, 2024	roberts m scot	sold (taxes)	-21,715	9.32	-2,330	chief scientific officer
Feb 02, 2024	harris matthew scott	sold (taxes)	-21,734	9.32	-2,332	chief medical officer
Feb 02, 2024	harris matthew scott	acquired	-	-	7,775	chief medical officer
Feb 01, 2024	garg vipin k	acquired	-	-	16,545	president and ceo
Feb 01, 2024	roberts m scot	sold (taxes)	-17,793	9.88	-1,801	chief scientific officer
Feb 01, 2024	roberts m scot	acquired	-	-	6,166	chief scientific officer
Feb 01, 2024	garg vipin k	sold (taxes)	-72,252	9.88	-7,313	president and ceo

Which funds bought or sold ALT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	sold off	-100	-534,000	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-268	2,545	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.34	-32,000	17,000	-%
Apr 23, 2024	GODSEY & GIBB, INC	sold off	-100	-6,874	-	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-62.00	1,018	-%
Apr 22, 2024	GERBER, LLC	added	10.17	-9,003	2,868,500	2.41%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	227,625	296,044	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	1,233,180	1,233,180	-%
Apr 22, 2024	WEALTH EFFECTS LLC	new	-	149,646	149,646	0.06%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-77.27	-19,000	5,000	-%

Are Funds Buying or Selling ALT?

Are funds buying ALT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALT

No. of Funds

Unveiling Altimmune Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	12.20%	8,649,270	SC 13G/A
Mar 05, 2024	millennium management llc	5.4%	2,911,937	SC 13G
Feb 14, 2024	ameriprise financial inc	7.79%	4,183,682	SC 13G
Feb 14, 2024	nuveen asset management, llc	0.01%	6,679	SC 13G/A
Feb 14, 2024	teachers advisors, llc	0.01%	6,679	SC 13G/A
Feb 14, 2024	tiaa cref investment management llc	0.01%	6,679	SC 13G/A
Feb 14, 2024	avidity partners management lp	0.0%	0	SC 13G/A
Feb 14, 2024	tang capital partners lp	5.1%	2,750,000	SC 13G/A
Feb 13, 2024	vanguard group inc	6.65%	3,571,972	SC 13G/A
Feb 12, 2024	janus henderson group plc	0.0%	273	SC 13G/A

Recent SEC filings of Altimmune Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	SC 13G/A	Major Ownership Report
Mar 27, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 05, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Altimmune Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Altimmune Inc News

Latest updates

Altimmune Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-89.8%	37,000	362,000	6,000	21,000	11,500	2,000	8,000	1,642,500	3,277,000	158,000	137,000	838,000	2,312,706	2,937,991	721,636	2,212,694	575,802	643,978	1,626,029	2,955,592	2,588,655
Operating Expenses	47.0%	33,660,000	22,902,000	18,013,000	21,780,000	22,984,000	24,754,000	20,403,000	19,531,000	27,262,000	33,362,000	25,001,000	15,699,000	13,062,501	21,262,213	19,139,606	9,519,448	4,887,912	11,917,358	5,176,913	5,284,153	29,934,635
S&GA Expenses	-4.0%	4,332,000	4,514,000	4,760,000	4,531,000	3,805,000	4,492,000	4,410,000	4,427,000	3,777,000	4,156,000	3,659,000	3,821,000	4,111,929	4,220,238	2,545,356	2,331,917	2,014,823	2,187,661	2,231,817	2,066,482	2,419,951
R&D Expenses	-8.0%	16,909,000	18,388,000	13,253,000	17,249,000	19,179,000	20,262,000	15,993,000	15,104,000	20,185,000	29,206,000	13,272,000	11,878,000	8,950,572	17,041,975	16,594,250	7,187,531	2,873,089	8,729,697	2,945,096	3,217,671	3,064,673
EBITDA Margin	-Infinity%	-228	-	-23.61	-23.47	-23.35	-23.96	-21.86	-21.87	-21.89	-24.15	-10.96	-9.07	-6.60	-	-	-	-	-	-	-	-
Interest Expenses	-93.1%	2,000	29,000	2,000	2,000	-183,000	64,000	65,000	62,000	-62,000	33,000	22,000	12,000	1,953	2,275	3,308	1,885	-	756	748	740	127,353
Income Taxes	-	-	-	-	-	3,000	-197,000	-	-	-	-	-	-	-110,346	-482,017	-1,578,782	-3,245,879	-	-58,500	-	-	-2,831,670
Earnings Before Taxes	-53.1%	-31,641,000	-20,671,000	-	-	-21,660,000	-23,713,000	-	-	-23,889,092	-33,510,000	-24,826,707	-14,864,108	-10,732,123	-18,252,152	-18,345,698	-7,131,528	-4,096,625	-10,997,812	-3,386,888	-2,097,306	-27,339,293
EBT Margin	-Infinity%	-229	-	-23.30	-23.30	-23.30	-24.02	-22.02	-22.02	-22.02	-24.36	-11.03	-9.13	-6.65	-	-	-	-	-	-	-	-
Net Income	-53.1%	-31,641,000	-20,671,000	-16,061,000	-20,074,000	-21,660,000	-23,516,000	-20,107,000	-19,430,000	-23,889,000	-33,510,000	-24,827,000	-14,864,000	-10,621,777	-17,770,135	-16,766,916	-3,885,649	-4,096,625	-10,939,312	-3,386,888	-2,097,306	-24,507,623
Net Income Margin	-Infinity%	-207	-	-18.44	-19.36	-19.21	-19.71	-21.98	-23.05	-22.02	-24.33	-10.94	-8.81	-5.99	-	-	-	-	-	-	-	-
Free Cashflow	19.3%	-16,533,000	-20,487,000	-19,379,000	-19,458,000	-17,344,000	-15,110,000	-16,723,000	-13,535,000	-22,114,000	-17,845,000	-26,618,000	-23,778,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	26.5%	211	167	183	187	207	225	210	206	219	237	257	264	245	233	103	54.00	54.00	56.00	62.00	65.00	55.00
Current Assets	37.0%	210	153	170	173	193	211	196	191	204	218	239	245	230	218	88.00	40.00	39.00	42.00	46.00	49.00	39.00
Cash Equivalents	55.6%	135	87.00	102	105	111	127	136	180	190	175	174	150	116	144	65.00	11.00	9.00	11.00	42.00	45.00	34.00
Net PPE	-14.9%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	2.3%	17.00	16.00	16.00	19.00	22.00	20.00	15.00	21.00	20.00	28.00	16.00	18.00	19.00	33.00	23.00	12.00	9.00	7.00	6.00	6.00	6.00
Current Liabilities	2.3%	12.00	12.00	11.00	15.00	17.00	16.00	14.00	19.00	18.00	19.00	9.00	10.00	12.00	6.00	5.00	6.00	4.00	2.00	3.00	4.00	5.00
Shareholder's Equity	29.1%	194	150	168	168	185	205	195	185	199	209	241	246	226	200	80.00	42.00	46.00	49.00	56.00	59.00	48.00
Retained Earnings	-7.3%	-466	-434	-414	-397	-377	-356	-332	-312	-293	-269	-235	-210	-186	-175	-158	-141	-137	-133	-122	-118	-116
Additional Paid-In Capital	12.7%	665	590	587	571	568	567	532	503	497	484	482	462	417	381	243	188	188	188	184	183	170
Shares Outstanding	33.7%	71.00	53.00	53.00	49.00	49.00	49.00	44.00	44.00	41.00	41.00	41.00	39.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	184	-	-	-	538	-	-	-	387	-	-	-	281	-	-	-	29.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	19.3%	-16,533	-20,487	-19,383	-19,407	-17,306	-15,050	-16,704	-13,526	-21,967	-17,775	-18,927	-19,569	-13,282	-9,504	-7,170	-4,347	-2,002	-2,426	-3,060	-2,112	-5,155
Share Based Compensation	-8.9%	2,469	2,710	2,786	2,675	1,892	2,128	2,048	2,033	1,319	1,497	1,485	1,218	710	1,320	331	215	279	288	290	408	69.00
Cashflow From Investing	-280.8%	-7,959	4,402	3,987	13,302	981	-25,403	-48,968	-9.00	24,869	18,411	25,078	19,165	-36,999	-47,888	6,098	6,563	-52.68	-28,216	-12.85	-4.25	-8.13
Cashflow From Financing	12273.1%	72,754	588	13,065	-302	-43.00	32,060	21,583	3,181	12,535	125	18,019	34,419	22,704	136,146	54,539	97.00	45.00	-55.79	-156	12,699	31,518

ALT Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues	$ 426	$ (68)
Operating expenses:
Research and development	65,799	70,538
General and administrative	18,137	17,134
Impairment loss on intangible assets	12,419
Total operating expenses	96,355	87,672
Loss from operations	(95,929)	(87,740)
Other income (expense):
Interest expense	(35)	(8)
Interest income	7,351	2,870
Other income (expense), net	166	(32)
Total other income (expense), net	7,482	2,830
Net loss before income taxes	(88,447)	(84,910)
Income tax expense (benefit)		(197)
Net loss	(88,447)	(84,713)
Other comprehensive income - unrealized gain (loss) on short-term investments	223	(187)
Comprehensive loss	$ (88,224)	$ (84,900)
Net loss per share, basic	$ (1.66)	$ (1.81)
Net loss per share, diluted	$ (1.66)	$ (1.81)
Weighted-average common shares outstanding, basic	53,246,937	46,926,349
Weighted-average common shares outstanding, diluted	53,246,937	46,926,349

ALT Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 135,117	$ 111,097
Restricted cash	41	34
Total cash, cash equivalents and restricted cash	135,158	111,131
Short-term investments	62,698	73,783
Accounts and other receivables	1,111	173
Income tax and R&D incentive receivables	3,742	2,368
Prepaid expenses and other current assets	6,917	5,358
Total current assets	209,626	192,813
Property and equipment, net	651	1,081
Indefinite-lived intangible asset		12,419
Other assets	363	615
Total assets	210,640	206,928
Current liabilities:
Accounts payable	2,070	4,804
Accrued expenses and other current liabilities	10,073	12,250
Total current liabilities	12,143	17,054
Noncurrent liabilities	4,398	4,581
Total liabilities	16,541	21,635
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 70,677,400 and 49,199,845 shares issued and outstanding as of December 31, 2023 and 2022, respectively	7	5
Additional paid-in capital	665,427	568,399
Accumulated deficit	(466,331)	(377,884)
Accumulated other comprehensive loss, net	(5,004)	(5,227)
Total stockholders' equity	194,099	185,293
Total liabilities and stockholders' equity	$ 210,640	$ 206,928

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

CEO	Dr. Vipin K. Garg Ph.D.
WEBSITE	https://altimmune.com
INDUSTRY	Biotechnology
EMPLOYEES	52

Altimmune Inc Frequently Asked Questions

What is the ticker symbol for Altimmune Inc? What does ALT stand for in stocks?

ALT is the stock ticker symbol of Altimmune Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Altimmune Inc (ALT)?

As of Thu Apr 25 2024, market cap of Altimmune Inc is 511.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers. The fair value of Altimmune Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Altimmune Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Altimmune Inc a good stock to buy?

The fair value guage provides a quick view whether ALT is over valued or under valued. Whether Altimmune Inc is cheap or expensive depends on the assumptions which impact Altimmune Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALT.

What is Altimmune Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, ALT's PE ratio (Price to Earnings) is -5.79 and Price to Sales (PS) ratio is 1.2 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Altimmune Inc's stock?

In the past 10 years, Altimmune Inc has provided -0.176 (multiply by 100 for percentage) rate of return.